BAB VIII

DAFTAR PUSTAKA

1. New Global Cancer Data: GLOBOCAN 2020. (2020, Maret).
2. Yang C, Chen L, Li C, Lynch M, Brisken C, Schmidt E (2010) 'Cyclin D1 enhances the response to estrogen and progesterone by regulating progesterone receptor expression', National Library of Medicine. Mol Cell Biol ;30(12):3111-25. Available at : https://pubmed.ncbi.nlm.nih.gov/20404095/
3. Siraj K, Parvathareddy S, Padmanaban A, Saeeda O, Nabil Siraj, Asma T, Fouad A, Dahish A, Khawla S (2021) High Expression of Cyclin D1 is an Independent Marker for Favorable Prognosis in Middle Eastern Breast Cancer. King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Onco Targets Ther 19:14:3309-3318. Available in https://pubmed.ncbi.nlm.nih.gov/34040395/
4. Sola B, Tchakarska G(2020) The double dealing of cyclin D1. Department of Human Genetics, McGill University Health Centre, McGill University Montreal Canada. Cell Cycle Vol. 19, N0. 2, 163 –178 Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961668/pdf/kccy-19-02-1706903.pdf
5. Panduan Tatalaksana Kanker Payudara. Edisi 2023. Perhimpunan Ahli Bedah Onkologi Indonesia.
6. Panduan penatalaksanaan kanker 2020. Perhimpunan ahli bedah onkologi Indonesia. 2020
7. Suyatno, Pasaribu emir T (2010) Bedah Onkologi Diagnostik dan Terapi, CV Sagung Seto, Jakarta
8. Parekh, Vishwas (2016) A microscopic landscape of the invasive breast cancer genome. Available in https://www.researchgate.net/publication/303908367_A_microscopic_landscape_of_the_invasive_breast_cancer_genome.
9. Ye, Jing, Wang W , Xu L , Duan X, Cheng Y, Xin L , Zhang H, Zhang S, Liu Yin (2020) A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer. Chin J Cancer Res ;29(4):351-360. Available in https://www.cjcrcn.org/article/html_9744.html

g D. Kanker Payudara di Indonesia, Masalah dan Penanggulangannya. Naskah Pidato ra Pengukuhan sebagai Guru Besar Bidang Ilmu Bedah onkologi Fakultas Kedokteran lasanuddin, Makassar, 27 Desember 2010.

11. Prihantono P, Rusli R, Christeven R, Faruk M (2022) Cancer Incidence and Mortality in a Tertiary Hospital in Indonesia: An 18- Year Data Review. Department of surgery Faculty of Medicine, Universitas Hasanudddin, Makassar Indonesia. Ethiop J Health Sci ;33(3):515-522.
12. Sukardja, I Dewa Gede (2000) Onkologi Klinik. Ed.2. Airlangga University Press
13. Peural E, Koivunen P, Haapasaari K, Bloigu R, Jukkola-Vuorinen A.(2013) 'The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer', Breast Cancer Research 2013, Department of Oncology and Radiotherapy, Oulu University Hospital, and University of Oulu. Breast Cancer Res 21;15(1)
14. Vanarsdale T. Boshoff C, Arndt K, Abraham R (2015) 'Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment', Clin Center Res 1;21(13):2905-10. www.aacrjournals.org
15. Qie shuo, Diehl A (2016) 'Cyclin D1, Cancer Progression and Opportunities in Cancer Treatment' Department of Biochemistry and Molecular Biology, Hollings Cancer Center, Medical University of South Carolina. J Mol Med (Berl); 94(12): 1313–1326.
16. Montallo franscesca ida, Amicis F (2020) Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma', Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy. Cells ;9(12):2648
17. Fu Maofu, Wang C, Zhiping L, Sakamaki T, Pestell R (2004) Minireview : Cyclin D1 : Normal and abnormal function. Endocrinology Vol 145, issue 12; Dec. 2004. Endocrinology, Volume 145, Issue 12, 1 December 2004, Pages 5439–5447.Avalaible in :https://doi.org/10.1210/en.2004-0959
18. Chen shuyi. Li L.(2022) 'Degradation strategy of cyclin D1 in cancer cells and the potential clinical application'. Sec. Molecular and Cellular Oncology. Department of Cell Biology, National Translational Science Center for Molecular Medicine Volume 12 – 2022, Fourth Military Medical University, Xi'an, China. Available https://doi.org/10.3389/fonc.2022.949688
19. Wood Daniel J, Endicott (2018) Structural insights into the functional diversity of the CDK–cyclin family. National Library of Medicine. Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6170502/

ınov G, and Ramadan K (2020) A unified model for the G1/S cell cycle transition. Medical ouncil Oxford Institute for Radiation Oncology, Department of Oncology, University of eic Acids Res.; 48(22): 12483–12501.

Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736809/

21. B. Ortiz, Garcia D (2017) 'Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma' Natiional Library of medicine. PLoS One ; 12(11): e0188068
Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687747/
22. Peurala E, Koivunen P, Haapasaari K, Bloigu Risto, Arja Vuorinencorresponding J (2013) The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. National Library of Medicine. Breast Cancer Res. 2013; 15(1): R5.
Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672746/
23. Ahlin C, Lundgren C, Jirström K (2017) High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Volume 164, pages 667–678. Available in https://link.springer.com/article/10.1007/s10549-017-4294-5
24. Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona Silvia P, Bernocchi O (2019) Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer. National Library of Medicine, Cells ;8(4):321. Available in https://pubmed.ncbi.nlm.nih.gov/30959874/
25. Kenny F, Hui R, Musgrove E, Gee J, Blamey R, Nicholson R, (1999) Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Cer Res 1999 Aug;5(8):2069-76. Available in https://aacrjournals.org/clincancerres/article/5/8/2069/287753/
26. Piezzo M, Cocco S, Caputo R, Cianniello D, Gioia G, Lauro V, (2020) Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. National Library of Medicine. Int J Mol Sci ; 21(18): 6479. Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7554788/
27. Jeffrey S, Becker T, Khan S, 4 Soon P, Hans N, Souza P, Powter B (2022) Prognostic and Predictive Value of CCND1/Cyclin D1 Amplification in Breast Cancer With a Focus on Postmenopausal Patients: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne); 13: 895729. Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249016/
28. Filho L, Savage K, Lambros M, James M, Steele D, Jones R, Dowsett M (2006) Cyclin D1 protein ion and CCND1 amplification in breast carcinomas: an immunohistochemical and in situ hybridisation analysis. Modern Pathology. Volume 19, Issue 7, Issue 7, Pages 999- able in https://www.sciencedirect.com/science/article/pii/S0893395222033579

29. Mohammadizadeh F, Hani M, Ranaee M, Bagheri M (2013) Role of Cyclin D1 in breast carcinoma. Natiional Library of medicine. J Res Med Sci; 18(12): 1021–1025.
Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3908521/

30. Aksoy A, Sevim M, Artas G (2023) The overexpression of cyclin D1 is a positive prognostic factor in advanced-stage breast carcinoma cases. Department of Medical Oncology, University of Health Sciences, Fethi Sekin City Hospital Health Applications Research Center, Elazig, Turkiye. North Clin Istanb ;10(6):726–733
Available in https://jag.journalagent.com/nci/pdfs/NCI-32657-RESEARCH_ARTICLE-AKSOY.pdf

31. Hunter Kent W, Crawford N, Alsarrac J (2008) Mechanisms of metastasis, Pubmed central. Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605099/

32. Valastyan S, Weinber A.(2017) Tumor Metastasi : Molecular Insights and Evolving Paradigms. https://www.sciencedirect.com/science/article/pii/S0092867411010853

33. Fuste' Noel P, Ferrezuelo F, Gari E (2016) Cyclin D1 promotes tumor cell invasion and metastasis by cytoplasmic mechanisms. Mol Cell Oncol.; 3(5): e1203471.
Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5068178/

34. Wu Jia-Shun, Jiang J, Chen B, Wang K, Tang Y, Liang X (2021) Plasticity of cancer cell invasion: Patterns and mechanisms.
Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573380/

35. Langsenlehner U, Hofmann G, Samonigg H, Krippl P, Renner W, Clar H (2005) Cyclin D1 genotype and breast cancer metastasis. Cancer Epidemiol Biomarkers Prev (2005) 14 (7): 1844.
Available in https://aacrjournals.org/cebp/article/14/7/1844/169697/Cyclin-D1-Genotype-and-Breast-Cancer-Metastasis1

36. Fuste' Noel P, Fernández-Hernández R, Cemeli T, Mirantes C, Pedraza N, Rafel M, Torres-Rosell J, Colomina N, Ferrezuelo F, Dolcet X, Gari E (2016) Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin. Nat Commun 16:7:11581.
https://pubmed.ncbi.nlm.nih.gov/27181366/

37. Ma N, Xu E, Luo Q, Song G (2023) Rac1: A Regulator of Cell Migration and a Potential Target for Cancer Therapy College of Bioengineering, Chongqing University, Chongqing, China. Molecules ;28(7):2976. Available in https://www.mdpi.com/journal/molecules

38. Hernandez E, De La Mota A (2010) Novel Inhibitors of Rac1 in Metastatic Breast Cancer, Puerto Rico health sciences journal 29(4):348-56. Available in https://www.researchgate.net/publication/49780027_Novel_Inhibitors_of_Rac1_in_Metastatic_Breast_Cancer

39. Langsenlehner U, Hofmann G, Samonigg H, Krippl P, Renner W, Clar H (2005) Cyclin D1 genotype and breast cancer metastasis. Journal of the National Comprehensive Cancer Network. 2005 Jul;14. Available in https://aacrjournals.org/cebp/article/14/7/1844/169697/Cyclin-D1-Genotype-and-Breast-Cancer-Metastasis1

40. Sasmita. W (2018). Besar Sampel untuk Proporsi. Available in https://slideplayer.info/slide/12087864/

41. Mathews A, Argani P, White M, Richarson A (2020). Staging & Grade John Hopkins medicine patology. Available in https://pathology.jhu.edu/breast/staging-grade/

42. Gru Ariel A, Allerd Craig D (2012) Molecular Pathology of Breast Cancer. Molecular Surgical Pathology pp 95–128. Available in https://link.springer.com/chapter/10.1007/978-1-4614-4900-3_6

43. Manisha Mohapatra, Yerraguntla Subramanya S. A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma. Journal of Cancer Research and Therapeutics. India. 2020

44. Butt Zeehan, Haider Furqan S, Arif S, Khan Raza M, Ashfaq U, Shahbaz U, Bukhari Hussain M (2012) Breast cancer risk factors: a comparison between pre-menopausal and post-menopausal women. National Library of Medicine. Available in https://pubmed.ncbi.nlm.nih.gov/22755371/

45. Parvin T, Das C, Choudhury M, Chattopadhyay Kumar B, Mukhopadhyay M (2019) Prognostic Utility of Cyclin D1 in Invasive Breast Carcinoma. Indian J Surg Oncol. (1): 167–173. Available in ncbi.nlm.nih.gov/pmc/articles/PMC6414594

46. Zangouri V, Akrami M, Tahmasebi S, Talei A, Hesaarooeih Ghaeni A (2018) Medullary Breast Carcinoma and Invasive Ductal Carcinoma: A Review Study. National Library of Medicine. Available in https://pubmed.ncbi.nlm.nih.gov/30046204/

47. Metha Ritu, Yadav Rashmi (2022) Carcinoma Breast: Correlation of Immunohistohemical Expression of Cyclin D1 and Its Correlation with Clinicopathological Parameters in Indian Patients at Tertiary Care Hospital. Available in https://clinmedjournals.org/articles/ijor/international-journal-of-oncology-research-ijor-5-044.php?jid=ijor

48. Oluogun A. W, Adedokun A. K, Oyenike A. M, Adeyeba A. O (2019) Histological classification, grading, staging, and prognostic indexing of female breast cancer in an African population: A 10-year retrospective study. Int J Health Sci (Qassim);13(4):3-9. Available in https://pubmed.ncbi.nlm.nih.gov/31341449/

49. Chung J, Noh Hany, Park Hwa K, Coi Eunhee, Han Airi (2014) Longer Survival in Patients with Breast Cancer with Cyclin D1 Over-Expression after Tumor Recurrence: Longer, but Occupied with Disease. National Library of Medicine. J Breast Cancer; 17(1): 47–53. Available in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988342/

50. El-Maqsoud NMRA, Moatasem M. (2010) Significance of Cyclin D1 overexpression and amplification in ductal hyperplasia, carcinoma in situ and invasive carcinoma in Egyptian female breast. Int J Cancer Res.;6:202–219.

51. Ravikumar G, Ananthamurthy A (2014) Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters. National Library of Medicine. J Cancer Res Ther ;10(3):671-5

Available in https://pubmed.ncbi.nlm.nih.gov/25313758/

LAMPIRAN 1

1. Prosedur pewarnaan jaringan biologis penderita kanker payudara

<table>
<tr>
<td>1. Potong blok paraffin dengan mikrotom pada ketebalan 3-4µ
  </td>
<td>2. Celupkan kedalam Waterbath
  </td>
</tr>
<tr>
<td>3. Ambil potongan jaringan dengan slide lalu tiriskan
  </td>
<td>4. Tulis pada slide kode sesuia blok paraffin
 
dengan pensil</td>
</tr>
<tr>
<td>5. Panaskan slde diatas Hot Plate selama 1 jam
  </td>
<td>6. Dinginkan slide lalu masukkan kedalam keranjang slide
7. Deparafinasi (Xylol I, Xylol II, Xylol III) masing-masing 5 menit
  </td>
</tr>
</table>

8. Rehidrasi (Alkohol 96%, Alkohol 80%, Alkohol 70%), masing-masing selama 5 menit

9. Cuci air mengalir selama 5 menit

10. Angkat dari air lalu masukkan slide kedalam larutan Blocking Endogen Peroksida, rendam selama 15 menit

11. Cuci air mengalir selama 5 menit

12. Masukkan keranjang berisi slide kedalam decloaking yang berisi larutan Antigen Retrival Decloaking Chamber, lalu letakkan slide pada rack holder

13. Masukkan rack holder kedalam decloaking, lalu tutup

14. Atur waktu yaitu selama 40 menit pada suhu 95 derajat.

15. Dinginkan, dengan mengeluarkan slide dari decloaking dan disimpan pada suhu ruangan
16. Setelah dingin , cuci dalam larutan PBS 2x masing-masing selama 5 menit
17. Tandai slide dengan memberi lingkaran sekitar jaringan

	
18. Atur slide pada baki slide 	19. Ambil satu per satu lalu tetesi Background Sniper lalu inkubasi selama 30 menit 

20. Buang larutan background sniper dengan cara ditiriskan pada tisu 21. Tetesi Antibody Primer lalu inkubasi selama 1 jam pada suhu ruang 22. Cuci PBS 2x selama 5 menit 	23. Tetesi Trekkie Universal lalu diamkan selama 30 menit 
24. Tiriskan pada tissue lalu tetesi Trekkkavidin-HRP lalu diamkan selama 30 menit 	25. Cuci PBS 2x dengan cara merendam slide selama 5 menit 
mbil menunggu pencucian, at larutan DAB dengan cara mpurkan cromogen DAB 1	27. Amati jaringan jika sudah menunjukkan warna coklat, langsung direndam ke dalam air selama 5 menit

tetes + Substrat buffer 1 ml (dicampur dalam tabung bersih) lalu tetesi ke jaringan. 	
28. Rendam dengan hematoxylin Meyer 5 menit 	29. Cuci air mengalir selama 5 menit 
30. Dehidrasi (Alkohol 70%, Alkohol 80%, Alkohol 96%) masing-masing 5 menit 	31. Clearing (Xylol I, Xylol II, Xylol III) 
32. Keringkan slide lalu tetesi dengan entelan lalu tutup dengan deck glass.	33. Amati di mikroskop

Lampiran 2 Data lengkap pasien penelitian

DAFTAR SAMPEL PENELITIAN															CYCLIN D1	
NO	RM	NO.PA	NAMA PASIEN	UMUR	PA	LETAK TUMOR	GRADE	ER	PR	HER-2	KI-67	METASTASIS	LOKASI METASTASIS	NILAI	KUALITAS	EKSPRESI +/-
1	133777	H19.1415	SITI AKBARI	69	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	1	POSITIF	POSITIF	NEGATIF	LOW			3	Weak	Negatif
2	104892	H20.002	NURJANNA	52	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	3	POSITIF	NEGATIF	NEGATIF	HIGH	YA	HEPAR, TULANG	8	Strong	Positif
3	126029	H20.027	NURLINA	44	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	1	POSITIF	NEGATIF	NEGATIF	LOW			6	Moderate	Positif
4	135426	H20.173	YURNI	37	INVASIVE DUCTAL BREAST CARCINOMA INSITU	DEXTRA	1	POSITIF	POSITIF	NEGATIF	LOW			0	Negatif	Negatif
5	137976	H20.339	KASMIATI	50	INVASIVE LOBULAR CARCINOMA MAMMAE BILATERAL	DEXTRA & SINISTRA	1	POSITIF	POSITIF	NEGATIF	LOW			8	Strong	Positif
6	136075	H20.322	INDARWATI	37	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	HIGH			7	Strong	Positif
7	138685	H20.376	WAHIDA	46	INVASIVE DUCTAL BREAST CARCINOMA	DEXTRA	2	POSITIF	POSITIF	NEGATIF	LOW	YA	HEPAR	7	Strong	Positif
8	149716	H20.778	HJ. SINAR	49	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	LOW	YA	HEPAR	6	Moderate	Positif
9	153358	H21.065	ST. RAMLAH	53	METASTASIS ADENOCARCINOMA	DEXTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	OTAK	7	Strong	Positif
10	151559	H21.074	SAORIA	31	INVASIVE DUCTAL BREAST CARCINOMA INSITU	SINISTRA	3	POSITIF	POSITIF	NEGATIF	LOW			7	Strong	Positif
11	147875	H21.109	FIDIATI	52	MIXED INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE AND MUCINOUS CARCINOMA	DEXTRA	2	POSITIF	POSITIF	NEGATIF	HIGH	YA	HEPAR	4	Moderate	Positif
12	114579	H21.223	NISA	62	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	3	POSITIF	NEGATIF	NEGATIF	HIGH	YA	HEPAR	7	Strong	Positif
13	151490	H21.172	JUNAIDA	45	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU	7	Strong	Positif
14	155704	H21.218	SYAMSIAH	34	INVASIVE LOBULAR CARCINOMA MAMMAE	SINISTRA	2	POSITIF	NEGATIF	NEGATIF	HIGH			6	Moderate	Positif
15	144882	H21.372	HJ. DOMA	54	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	HIGH			6	Moderate	Positif
16	143828	H21.390	DAHNAR NURDIN	42	METASTASIS ADENOCARCINOMA	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	TULANG	8	Strong	Positif
17	72374	H21.450	RAJAWANG	62	METAPLASTIC CARCINOMA MAMMAE WITH MICROGLANDULAR FEATURE	SINISTRA	1	POSITIF	POSITIF	NEGATIF	LOW			3	Weak	Negatif
18	159955	H21.525	EVI PAMOSE	54	MALIGNOUS CARCINOMA MAMMAE WITH MICROPAPILLARY FEATURE	SINISTRA	2	POSITIF	POSITIF	NEGATIF	LOW			8	Strong	Positif
19	170450	H21.974	SUNIATI	48	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	LOW	YA	HEPAR	6	Moderate	Positif
20	167610	H21.776	NINGSIH RASYID	70	INVASIVE LOBULAR CARCINOMA MAMMAE	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH			7	Strong	Positif
21	183171	H22.920	A. RAMLAH BUDY	54	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	2	POSITIF	POSITIF	NEGATIF	HIGH			7	Strong	Positif
22	182963	H22.799	WA ODE HATIMAH	47	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU	5	Moderate	Positif
23	171845	H22.668	SURYANI	44	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	1	POSITIF	POSITIF	NEGATIF	LOW			3	Weak	Negatif
24	180928	H22.536	ST.RATIMLIA	48	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	1	NEGATIF	POSITIF	NEGATIF	HIGH			0	Negatif	Negatif
25	181347	H22.583	DARMIATI	44	INVASIVE PAPILLARY CARCINOMA MAMMAE SINISTRA	SINISTRA	2	POSITIF	POSITIF	NEGATIF	HIGH			8	Strong	Positif
26	178821	H22.441	SUMARNI	43	INVASIVE LOBULAR CARCINOMA MAMMAE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	HIGH			7	Strong	Positif
27	76185	H22.528	FATMAWATI	38	ADENOCARCINOMA MAMMAE MUCINOSUM	SINISTRA	1	POSITIF	POSITIF	NEGATIF	LOW			0	Negatif	Negatif
28	184572	H22.895	NISWATI NURDIN	46	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	NEGATIF	POSITIF	NEGATIF	HIGH			3	Weak	Negatif
29	171015	H22.434	BAHRAH	60	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU	6	Moderate	Positif
30	177488	H22.279	MAYASARI	41	INVASIVE DUCTAL BREAST CARCINOMA	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU	7	Strong	Positif
31	170492	H22.020	ST HASNAH	59	SECRETORY CARCINOMA	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU	7	Strong	Positif
32	173596	H22.550	MINA	70	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	HIGH	YA	TULANG	7	Strong	Positif
33	85827	H19.450	NAHURIA	55	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	2	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU, TULANG	4	Moderate	Positif
34	152510	H21.1027	RABIAH	58	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	LOW	YA	TULANG	7	Strong	Positif
35	799715	P18.0058	ST NURSIAH	42	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	2	POSITIF	POSITIF	NEGATIF	HIGH	YA	HEPAR, TULANG	7	Strong	Positif
36	909897	P21.1270	SERLIANA KONDO	45	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE BILATERAL	SINISTRA	2	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU, TULANG	7	Strong	Positif
37	944665	P22.0070	UMMY HAYATI	37	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	2	POSITIF	POSITIF	NEGATIF	LOW	YA	PARU, TULANG	7	Strong	Positif
38	958576	P22.3872	MARLIAH	46	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	1	POSITIF	POSITIF	NEGATIF	LOW			0	Negatif	Negatif
39	792073	P22.2674	HASMIAH ACHMAD	40	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	1	POSITIF	POSITIF	NEGATIF	LOW			2	Weak	Negatif
40	935498	P21.2364	LINCE TIRANDA	65	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	3	POSITIF	NEGATIF	NEGATIF	HIGH	YA	TULANG	4	Moderate	Positif
41	767517	P19.4447	YOHANA TURUPADANG	51	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	LOW	YA	PARU, TULANG	7	Strong	Positif
42	781133	P19.4731	HAMSINA DG KACA	49	INVASIVE DUCTAL BREAST CARCINOMA	SINISTRA	2	NEGATIF	POSITIF	NEGATIF	HIGH	YA	TULANG	7	Strong	Positif
43	885602	P19.3754	FITRAWATI LATIEF	42	INVASIVE DUCTAL BREAST CARCINOMA	SINISTRA	2	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU	7	Strong	Positif
44	895551	P19.4522	RATNA A	56	INVASIVE DUCTAL BREAST CARCINOMA	DEXTRA	2	POSITIF	NEGATIF	NEGATIF	HIGH			7	Strong	Positif
45	907210	P20.0245	HAJAR	54	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	1	POSITIF	POSITIF	NEGATIF	LOW	YA	PARU, TULANG	7	Strong	Positif
46	975206	P23.0030	SITTI NURSIA P	60	INVASIVE DUCTAL BREAST CARCINOMA	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	TULANG	7	Strong	Positif
47	992064	P23.3783	FARIDA	48	INVASIVE DUCTAL BREAST CARCINOMA	DEXTRA	1	POSITIF	POSITIF	NEGATIF	LOW			7	Strong	Positif
48	902837	P22.1739	SANIASA	58	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH			7	Strong	Positif
49	427894	P22.1324	SITI NURHANI	46	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	3	POSITIF	POSITIF	NEGATIF	LOW			7	Strong	Positif
50	945626	P21.2968	MAGDALENA	61	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	HIGH			7	Strong	Positif
51	909382	P21.1566	ANTHO	57	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	PARU	7	Strong	Positif
52	844501	P20.0071	NURLIA	40	INVASIVE DUCTAL BREAST CARCINOMA	DEXTRA	1	POSITIF	POSITIF	NEGATIF	LOW			7	Strong	Positif
53	884354	P19.2995	MASTUTI PESOA	56	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	2	POSITIF	POSITIF	NEGATIF	LOW					
54	98443	P19.3195	NETHI	63	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	2	POSITIF	POSITIF	NEGATIF	LOW					
55	871333	P19.1226	HAYANA	55	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	1	POSITIF	POSITIF	NEGATIF	HIGH					
56	831108	P21.1359	SARIDAH	45	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	DEXTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	TULANG			
57	891882	P19.4880	ST. NORUA	57	INVASIVE DUCTAL BREAST CARCINOMA OF NO SPECIAL TYPE	SINISTRA	3	POSITIF	POSITIF	NEGATIF	HIGH	YA	TULANG			